Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) : Long-term effect on kidney function in patients with type 2 diabetes. / Von Scholten, Bernt Johan; Hansen, Tine Willum; Goetze, Jens Peter; Persson, Frederik; Rossing, Peter.
I: Journal of Diabetes and its Complications, Bind 29, Nr. 5, 01.07.2015, s. 670-674.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide 1 receptor agonist (GLP-1 RA)
T2 - Long-term effect on kidney function in patients with type 2 diabetes
AU - Von Scholten, Bernt Johan
AU - Hansen, Tine Willum
AU - Goetze, Jens Peter
AU - Persson, Frederik
AU - Rossing, Peter
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. Methods We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR (51Cr-EDTA plasma clearance). Results Patients were 61.5 (10.0) years and HbA1c 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m2 and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m2, independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA1c (p ≥ 0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. Conclusions Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. Trial registration ClinicalTrials.gov identifier: NCT01499108.
AB - Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. Methods We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR (51Cr-EDTA plasma clearance). Results Patients were 61.5 (10.0) years and HbA1c 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m2 and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m2, independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA1c (p ≥ 0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. Conclusions Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. Trial registration ClinicalTrials.gov identifier: NCT01499108.
KW - Glomerular filtration rate
KW - GLP-1
KW - Kidney function
KW - Liraglutide
KW - MR-proANP
KW - Urinary albumin excretion rate
UR - http://www.scopus.com/inward/record.url?scp=84930572421&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2015.04.004
DO - 10.1016/j.jdiacomp.2015.04.004
M3 - Journal article
C2 - 25935863
AN - SCOPUS:84930572421
VL - 29
SP - 670
EP - 674
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
SN - 1056-8727
IS - 5
ER -
ID: 257058522